Clinical Experience with Berotralstat in Patients with Hereditary Angioedema with Normal C1-Esterase Inhibitor: A Commented Case Series
Henry Kanarek,Drew Mutschelknaus
DOI: https://doi.org/10.2147/jaa.s445893
2024-02-23
Journal of Asthma and Allergy
Abstract:Henry J Kanarek, &ast Drew Austin Saville Mutschelknaus &ast Kanarek Allergy, Asthma & Immunology, Leawood, KS, USA &astThese authors contributed equally to this work Correspondence: Henry J Kanarek, Tel +1 (913) 451-8555, Fax +1 (913) 327-8553, Email Hereditary angioedema (HAE) is a rare genetic disorder characterized by potentially life-threatening episodes of swelling. Most HAE cases are caused by deficient (type I) or dysfunctional (type II) C1-esterase inhibitor (C1-INH) protein. However, some patients present with a subtype of HAE that is associated with normal plasma levels of functional C1-INH protein and complement component 4 (HAE-nC1INH). Treatment of HAE-nC1INH is driven by clinical experience as robust clinical trial data to inform treatment decisions are lacking in this population. This retrospective case series assessed clinical features and treatment outcomes in 15 patients with HAE-nC1INH who initiated long-term prophylaxis with oral berotralstat 150 mg once daily as part of their disease management pathway. Most patients were female (93%), with a median age of 49 years. All patients experienced abdominal swelling attacks. On average, patients tried a mean of 4 different treatments for their HAE, including berotralstat. Although most patients associated prophylactic and on-demand medications that target the bradykinin pathway with improvements in the frequency and/or severity of attacks, treatment outcomes varied considerably between patients, highlighting the importance of a personalized approach to disease management. In this case series, berotralstat was an effective prophylactic treatment option in most patients with HAE-nC1INH. Further studies are required to demonstrate the potential efficacy, safety, and impact on quality of life of currently approved HAE therapies in patients with HAE-nC1INH. Keywords: hereditary angioedema, normal C1-esterase inhibitor, prophylaxis, berotralstat, lanadelumab, plasma-derived C1-esterase inhibitor, abortive therapy Patients with hereditary angioedema (HAE) experience unpredictable and potentially life-threatening recurrent episodes of swelling that generally affect the extremities, genitals, abdomen, larynx, and face. 1–3 Some patients present with a form of HAE with normal C1-inhibitor (HAE-nC1INH), which is associated with normal plasma levels of functional C1-inhibitor (C1-INH) protein and complement component 4 (C4). 3 Mutations in genes such as coagulation factor XII (FXII), plasminogen, angiopoietin 1, kininogen 1, heparan sulfate glucosamine 3-O-sulfotransferase-6, and myoferlin have been identified in several patients with HAE-nC1INH. Some of these genes are involved with the production of bradykinin. However, the prevalence and pathophysiology of the disease are less clear than in HAE with low serum level or functional deficiency in C1 inhibitor (HAE-C1INH), and the etiology of the disease remains unknown for many patients. 1,4–9 Additionally, HAE-nC1INH is more challenging to definitively diagnose than HAE-C1INH because diagnosis reliant on genetic testing only identifies a small subset of patients with the disease. 8,10 Additionally, these genetic tests are not readily available in all clinical practices. 1 Overall, the swelling attacks experienced by patients with HAE-nC1INH and patients with HAE-C1INH are similar, but subtle differences exist between them 1,7 Patients with HAE-nC1INH typically present with their first symptoms of disease in late adolescence to early adulthood, while the first symptoms of HAE-C1INH typically appear in childhood. 1,5,11 Furthermore, patients with symptomatic HAE-nC1INH are predominately female, with exposure to estrogens frequently linked to the onset and exacerbation of swelling attacks. 4,5,12–14 Edema of the face, tongue, and oropharynx have been documented more frequently in patients with HAE-nC1INH than in patients with HAE-C1INH. 1,6,7,15,16 A review of 57 French patients with confirmed FXII mutations indicated that 74% of patients experienced HAE attacks affecting the ear, nose, and throat, while 80% experienced abdominal attacks 13 despite some experts suggesting that patients with HAE-nC1INH typically have fewer abdominal symptoms. 1 The occurrence of non-specific presenting symptoms in patients with HAE-nC1INH often results in misdiagnosis, ongoing treatment with inappropriate therapy (ie, antihistamines, corticosteroids, adrenaline) and/or unnecessary procedures (ie, surgical intervention). 5,17–19 Furthermore, the absence of robust data from clinical trials evaluating HAE therapies in patients with HAE-nC1INH means that, once diagnosis is suspected, the treatment of this patient population is based on clinical expe -Abstract Truncated-
immunology,allergy,respiratory system